Oppenheimer & Co. Inc. reduced its position in Bottomline Technologies (NASDAQ:EPAY) by 48.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,825 shares of the technology company’s stock after selling 118,272 shares during the period. Oppenheimer & Co. Inc. owned approximately 0.31% of Bottomline Technologies worth $6,270,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Global X Management Co. LLC boosted its position in Bottomline Technologies by 89.9% during the 1st quarter. Global X Management Co. LLC now owns 46,858 shares of the technology company’s stock worth $1,816,000 after purchasing an additional 22,177 shares during the period. Wells Fargo & Company MN boosted its position in Bottomline Technologies by 167.3% during the 1st quarter. Wells Fargo & Company MN now owns 277,895 shares of the technology company’s stock worth $10,767,000 after purchasing an additional 173,930 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Bottomline Technologies during the 1st quarter worth $1,349,000. Comerica Bank boosted its position in Bottomline Technologies by 19.3% during the 1st quarter. Comerica Bank now owns 78,184 shares of the technology company’s stock worth $3,149,000 after purchasing an additional 12,626 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Bottomline Technologies during the 1st quarter worth $103,000. Institutional investors own 97.24% of the company’s stock.
Top Insurance Stocks For 2019: Industrial Select Sector SPDR ETF (XLI)
Advisors' Opinion:- [By ]
Shares of the Industrials Select Sector SPDR (NYSE: XLI) returned 28% over the year to mid-February and the sector trades a premium of 22% on its long-term forward multiple.
- [By Todd Shriber, ETF Professor]
With June being a risk-off kind of month, some cyclical sectors often lag this month. The Industrial Select Sector SPDR (NYSE: XLI), for example, averages June losses of more than 1 percent.
- [By Todd Shriber, ETF Professor]
The broader industrial sector has faced challenges this year, but the recent performance of the Industrial Select Sector SPDR (NYSE: XLI) indicates some investors are turning positive on the group. XLI, the largest industrial exchange traded fund, is up 5 percent over the past week.
Top Insurance Stocks For 2019: Galmed Pharmaceuticals Ltd.(GLMD)
Advisors' Opinion:- [By Shane Hupp]
Here are some of the media stories that may have effected Accern’s rankings:
Get Galmed Pharmaceuticals alerts: Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltd's (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.
- [By George Budwell]
Shares of the clinical-stage biotech Galmed Pharmaceuticals (NASDAQ:GLMD) are on absolute fire this morning, thanks to a positive midstage trial readout for its experimental nonalcoholic steatohepatitis (NASH) drug Aramchol. Specifically, the company reported that patients receiving the 400 mg dose of Aramchol exhibited a significant reduction in liver fat over the study period compared to those taking a placebo. Curiously, though, patients receiving the higher dose of 600 mg apparently only showed a statistically significant drop in liver fat relative to placebo patients in a post-hoc analysis, according to the press release.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Insurance Stocks For 2019: Guidewire Software, Inc.(GWRE)
Advisors' Opinion:- [By Max Byerly]
Shares of Guidewire Software Inc (NYSE:GWRE) have received an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $95.00.
- [By Stephan Byrd]
TRADEMARK VIOLATION NOTICE: “Insider Selling: Guidewire Software (GWRE) Insider Sells 209 Shares of Stock” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3365485/insider-selling-guidewire-software-gwre-insider-sells-209-shares-of-stock.html.
- [By Max Byerly]
Verition Fund Management LLC bought a new position in shares of Guidewire Software Inc (NYSE:GWRE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,731 shares of the technology company’s stock, valued at approximately $221,000.
- [By Logan Wallace]
Guidewire Software Inc (NYSE:GWRE) shares reached a new 52-week high and low during mid-day trading on Wednesday . The company traded as low as $95.26 and last traded at $93.56, with a volume of 7356 shares changing hands. The stock had previously closed at $94.77.
- [By Motley Fool Transcribers]
Guidewire Software Inc (NYSE:GWRE)Q2 2019 Earnings Conference CallMarch 06, 2019, 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
No comments:
Post a Comment